TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00203359 |
Recruitment Status :
Completed
First Posted : September 20, 2005
Last Update Posted : April 24, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer's Disease | Drug: etanercept given by perispinal administration | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 15 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Etanercept for Alzheimer's-Type Memory Loss Pilot Study |
Study Start Date : | September 2004 |
Study Completion Date : | April 2006 |

- ADAS-Cog
- SIB
- MMSE
- Category fluency
- other neuropsychological tests

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- NINCDS-ADRDA Criteria for Alzheimer's disease
- CT or MRI consistent with AD
Exclusion Criteria:
- active infection
- CHF
- demyelinating disease
- uncontrolled diabetes mellitus
- vascular dementia
- clinically significant neurologic disease other than AD
- Hachinski >4
- history of lymphoma
- TBC
- wbc<2500
- platelets<100,000
- HCT<30
- pregnancy
- premenopausal, fertile not on acceptable birth control
- change in neuroactive medication within 4 weeks of study initiation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00203359
United States, California | |
Edward Tobinick, MD (private medical office) | |
Los Angeles, California, United States, 90095 |
Principal Investigator: | Edward L Tobinick, MD | unaffiliated (Assistant Clinical Professor of Medicine, David Geffen School of Medicine at UCLA) |
ClinicalTrials.gov Identifier: | NCT00203359 |
Other Study ID Numbers: |
10005 |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | April 24, 2006 |
Last Verified: | April 2006 |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Etanercept Anti-Inflammatory Agents, Non-Steroidal |
Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Gastrointestinal Agents Immunosuppressive Agents Immunologic Factors |